Chapter 5.1 – Malaria issues in special hosts-Children: Canadian recommendations for the prevention and treatment of malaria

An Advisory Committee Statement (ACS) from the
Committee to Advise on Tropical Medicine and Travel (CATMAT)

Preamble

The Committee to Advise on Tropical Medicine and Travel (CATMAT) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to tropical infectious disease and health risks associated with international travel. PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and medical practices, and is disseminating this document for information purposes to both travellers and the medical community caring for travellers.

Persons administering or using drugs, vaccines, or other products should also be aware of the contents of the product monograph(s) or other similarly approved standards or instructions for use. Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) or other similarly approved standards or instructions for use by the licensed manufacturer(s). Manufacturers have sought approval and provided evidence as to the safety and efficacy of their products only when used in accordance with the product monographs or other similarly approved standards or instructions for use.

Chapter 5: Malaria issues in special hosts

5.1 Prevention in special hosts—children

Malaria prevention in children

Health care providers should clearly advise travellers of the risks of taking young children to areas with Plasmodium falciparum malaria. The majority of the over 650,000 deaths per year due to malaria are among childrenReference 1. A study found that malaria was the most common cause of febrile illness (35%) among returned pediatric travellers, and the most common single diagnosis overall (8%)Reference 2; however these findings cannot be generalized to all children travelling internationally. Travel to sub-Saharan Africa accounts for the vast majority of childhood cases of falciparum malaria, with most travellers visiting friends and relativesReference 2, Reference 3, Reference 4. Malaria also disproportionately affects children. Of the Canadians diagnosed with malaria who were reported to the Public Health Agency of Canada from 1998 to 2008, 23% were 19 years old or younger whereas only 8.7% of international travellers in 2011 were in that age groupReference 5. From August 2001 to August 2012, 195 cases of severe or complicated malaria were reported to the Canadian Malaria Network (CMN). Of these, 21.1% were children (< 18 years old), and 11.6% were 0 to 4 years old (Personal communication, A. McCarthy and J. Geduld, 2012).

Of the 7,542 malaria cases reported between 2006 and 2010 to the Centers for Disease Control and Prevention (CDC) in the United States, 1,418 (18.0%) were children (< 18 years old) and 360 (4.8%) were aged 0 to 4 years old (Personal communication, K. Cullen and P. Arguin, 2012; Domestic Response Unit, Malaria Branch, Division of Parasitic Diseases, CDC and Prevention, United States).

Malaria can present with nonspecific symptoms that mimic other common childhood diagnoses, leading to delays in diagnosis. Severe or complicated malaria, such as cerebral malaria, severe anemia, shock or even death, may develop more quickly in childrenReference 6. CMN data from June 2001 to September 2011 indicate that 22% of the complicated malaria cases requiring treatment with intravenous quinine or artesunate were in children, the majority of whom were foreign-born (61%)Reference 7.

To reduce the risk of infection when travel to malaria-endemic areas is unavoidable, all children should be well protected against mosquito bites (see Chapter 3) and receive appropriate malaria chemoprophylaxisReference 7, Reference 8. Infants do not receive sufficient medication through breast milk to protect them and should be prescribed antimalarial drugs even if their mother is taking antimalarialsReference 9, Reference 10.

Making sure that young children take antimalarial drugs may be difficult because of the lack of pediatric formulations and the unpleasant taste. Malaria tablets may be crushed and mixed with chocolate syrup, jam, cereal, bananas or formula to mask the taste. Prescribe sufficient tablets to allow a few doses to be vomited or spat out, with clear instructions as to when doses that were not successfully ingested should be repeated. Health care providers should consider enlisting the help of compounding pharmacies that can pre-cut tablets and/or crush and insert portions into capsules to increase the accuracy and ease of dosing.

Deaths due to inadvertent overdose have been reported; these medications should, therefore, be kept out of reach of infants and children and stored in childproof containersReference 11.

Families who are travelling over the long term should be told how to adjust the dose of medications to allow for an increase in children’s weight over time.

Chemoprophylaxis for children

Chloroquine is the preferred chemoprophylactic agent in areas with chloroquine-sensitive malaria (see Appendix I for specific recommendations for areas). Chloroquine sulfate (e.g. Nivaquine®) is widely available as syrup in malaria-endemic areas, and this is often more easily administered to children than are tablets. However, it is not available in Canada, and those purchasing products outside of Canada need to take care to minimize the risk of counterfeit medication (see “Preventing Malaria in the Long-Term Traveller or Expatriate”). If parents plan to use this syrup, inform them that the dose must be carefully determined according to the child’s weight and that there is a risk of overdosing.

Mefloquine is one of the drugs of choice in chloroquine-resistant regions (see Appendix I for specific recommendations for different areas); however, there are no studies that analyze its bioavailability and rate of metabolism in children. Although the manufacturer recommends that mefloquine not be given to children smaller than 5 kg (11 lb), mefloquine should be considered for all children at high risk of acquiring chloroquine-resistant P. falciparum, at a dose of 5 mg base/kg once weeklyReference 12.

Young children are less likely to suffer major neuropsychiatric side effects from mefloquineReference 13 but may be more likely to have emesisReference 14.

While chloroquine and mefloquine may exacerbate seizure disorders, in which case other agents should be used, there is no evidence that febrile seizures in children are a contraindication to these drugs.

Atovaquone-proguanil is licensed for the prophylaxis and treatment of malaria in children weighing 11 kg (25 lb) or more or who are older than 3 yearsReference 15. Clinical trials using atovaquone-proguanil to treat malaria in children weighing as low as 5 kg (11 lb) suggest it may be safe for infants of this size when requiredReference 16. Daily doses for small infants have been extrapolated from those used in treatment trials (one-quarter of the treatment dose, or 5 mg/kg/doses and 2 mg/kg/doses of the atovaquone and proguanil components, respectively). Based on a pediatric tablet of 62.5 mg atovaquone/25 mg proguanil, the daily doses is half of a pediatric tablet for those children weighing 5 kg to 8 kg (11–17 lb) and three-quarters of a pediatric tablet for those children weighing 8 kg to 10 kg (17–22 lb)Reference 16.

Doxycycline has been studied as pediatric prophylactic medicationReference 17. It can be used at a daily dose of 2 mg/kg (maximum: 100 mg/d) in children aged 8 years and olderReference 9, Reference 18. Primaquine can be given to children 9 years and older who are unable to take any of the first-line prophylactic agentsReference 19, although it is not licensed in Canada for this indication. As there is no age limit for primaquine when used for radical cure of P. vivax or P. ovale, it may be an option for children of any age as long as they have been screened for adequate glucose-6-phosphate dehydrogenase (G6PD) levels. Consultation with a travel medicine or infectious disease expert is advisable unless the prescriber has experience with this medication in the pediatric population.

Table 5.1.1: Evidence-based medicine recommendations
Recommendation EBM rating

Abbreviation: EBM, evidence-based medicine; PPM, personal protective measures.

Note: For a description of the categories and quality of evidence of the recommendations, see Appendix IV.

Young children should avoid travel to areas with significant malaria transmission, particularly of chloroquine-resistant malariaReference 9. C III
Effective PPM should be used by all children who travel to malaria-endemic areasReference 20. A I
For children travelling to or residing in chloroquine-resistant areas, mefloquine, doxycycline (≥ 8 years) and atovaquone–proguanil (≥ 5 kg) are the drugs of choice for chemoprophylaxis Reference 12, Reference 15, Reference 17, Reference 21. A I
Primaquine chemoprophylaxis may be suitable for children who are unable to take any of the first-line prophylactic agentsReference 19. B II

References

Reference 1

World Health Organization. World Malaria Report 2011. 2011.

Return to reference 1 referrer

Reference 2

Hagmann S, Neugebauer R, Schwartz E, Perret C, Castelli F, Barnett ED, et al. Illness in children after international travel: analysis from the GeoSentinel Surveillance Network. Pediatrics 2010 May;125(5):e1072–e1080.

Return to reference 2 referrer

Reference 3

Ladhani S, Aibara RJ, Riordan FA, Shingadia D. Imported malaria in children: a review of clinical studies. Lancet Infect Dis 2007 May;7(5):349–57.

Return to reference 3 referrer

Reference 4

Stager K, Legros F, Krause G, Low N, Bradley D, Desai M, et al. Imported malaria in children in industrialized countries, 1992–2002. Emerg Infect Dis 2009 Feb;15(2):185–91.

Return to reference 4 referrer

Reference 5

Statistics Canada. Characteristics of International Travelers: Custom Extraction. 2011.

Return to reference 5 referrer

Reference 6

Maitland K, Marsh K. Pathophysiology of severe malaria in children. Acta Trop 2004 Apr;90(2):131–40.

Return to reference 6 referrer

Reference 7

McCarthy AE, Plourde P, Kuhn S., Bodie M. Parenteral quinine for severe malaria: Five year surveillance data from the Canadian Malaria Network. 10th Conference of the International Society of Travel Medicine. 10th Conference of the International Society of Travel Medicine, [Abstract No. FC02.01]. 2007.

Return to reference 7 referrer

Reference 8

Committee to Advise on Tropical Medicine and Travel. Statement on personal protective measures to prevent arthropod bites. Can Commun Dis Rep 2012;38 (ASC-3):1–18.

Return to reference 8 referrer

Reference 9

American Academy of Pediatrics. Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed. Illinois: American Academy of Pediatrics; 2009.

Return to reference 9 referrer

Reference 10

Martindale. The Complete Drug Reference. 32nd Ed. ed. London: Pharmaceutical Press; 2008.

Return to reference 10 referrer

Reference 11

Smith ER, Klein-Schwartz W. Are 1–2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 2005 May;28(4):437–43.

Return to reference 11 referrer

Reference 12

Centers for Disease Control. Information for health care providers: preventing malaria in infants and children. 2006.

Return to reference 12 referrer

Reference 13

Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Ann Trop Paediatr 1996 Dec;16(4):281–6.

Return to reference 13 referrer

Reference 14

Stauffer WM, Kamat D, Magill AJ. Traveling with infants and children. Part IV: insect avoidance and malaria prevention. J Travel Med 2003 Jul;10(4):225–40.

Return to reference 14 referrer

Reference 15

Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004 Jun 15;38(12):1716–23.

Return to reference 15 referrer

Reference 16

Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007 Feb;76(2):208–23.

Return to reference 16 referrer

Reference 17

Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet 1987 May 23;1(8543):1161–4.

Return to reference 17 referrer

Reference 18

Rietveld AE. Special groups: pregnant women, infants, and young children. In: Schlagenhauf P, editor. Traveller's medicine. 315 ed. Hamilton: BC Decker Inc; 2001.

Return to reference 18 referrer

Reference 19

Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995 Jun;171(6):1569–75.

Return to reference 19 referrer

Reference 20

Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002 Jul 4;347(1):13–8.

Return to reference 20 referrer

Reference 21

Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001 Oct 1;33(7):1015–21.

Return to reference 21 referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: